146 related articles for article (PubMed ID: 24300041)
1. An economic analysis: is fidaxomicin worth the cost?
Shah H; Doyle JJ; Belletti DA
Clin Infect Dis; 2014 Feb; 58(4):603-4. PubMed ID: 24300041
[No Abstract] [Full Text] [Related]
2. Is fidaxomicin worth the cost? An economic analysis.
Bartsch SM; Umscheid CA; Fishman N; Lee BY
Clin Infect Dis; 2013 Aug; 57(4):555-61. PubMed ID: 23704121
[TBL] [Abstract][Full Text] [Related]
3. Is fidaxomicin worth the cost? The verdict is still out!
Hartzema AG; Chen C
Clin Infect Dis; 2014 Feb; 58(4):604-5. PubMed ID: 24300046
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of fidaxomicin for Clostridium difficile treatment.
Simon MS
Clin Infect Dis; 2014 Feb; 58(4):603. PubMed ID: 24300043
[No Abstract] [Full Text] [Related]
5. A pharmacy concierge service to optimize fidaxomicin therapy.
Bookstaver PB; Capino AC; Bookstaver NK
Am J Health Syst Pharm; 2014 Jun; 71(12):986-7. PubMed ID: 24865752
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.
Nathwani D; Cornely OA; Van Engen AK; Odufowora-Sita O; Retsa P; Odeyemi IA
J Antimicrob Chemother; 2014 Nov; 69(11):2901-12. PubMed ID: 25096079
[TBL] [Abstract][Full Text] [Related]
7. Fidaxomicin in the treatment of Clostridium difficile-associated diarrhoea.
Sclar DA; Robison LM; Oganov AM; Schmidt JM; Bowan KA; Castillo LV
Clin Drug Investig; 2013 Mar; 33(3):229. PubMed ID: 23386229
[No Abstract] [Full Text] [Related]
8. Fidaxomicin in the treatment of Clostridium difficile-associated diarrhoea.
Greig J
Clin Drug Investig; 2013 Jan; 33(1):93-4. PubMed ID: 23233241
[No Abstract] [Full Text] [Related]
9. Reply to Simon, Shah et al, and Hartzema and Chen.
Bartsch SM; Umscheid CA; Fishman N; Lee BY
Clin Infect Dis; 2014 Feb; 58(4):605-7. PubMed ID: 24300044
[No Abstract] [Full Text] [Related]
10. Fewer recurrent infections of C. difficile seen with fidaxomicin. This new class of antibiotic--the macrocycles--has a greater sustained response against re-infection than vancomycin.
Morrow T
Manag Care; 2011 Jul; 20(7):49-50. PubMed ID: 21848202
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
Watt M; Dinh A; Le Monnier A; Tilleul P
J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
[TBL] [Abstract][Full Text] [Related]
12. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile.
Eyre DW; Babakhani F; Griffiths D; Seddon J; Del Ojo Elias C; Gorbach SL; Peto TE; Crook DW; Walker AS
J Infect Dis; 2014 May; 209(9):1446-51. PubMed ID: 24218500
[TBL] [Abstract][Full Text] [Related]
13. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and Treatment of Clostridioides (Clostridium) difficile Infection in Adults in 2020.
Rao K; Malani PN
JAMA; 2020 Apr; 323(14):1403-1404. PubMed ID: 32150234
[No Abstract] [Full Text] [Related]
15. A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.
Burton HE; Mitchell SA; Watt M
Pharmacoeconomics; 2017 Nov; 35(11):1123-1140. PubMed ID: 28875314
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States.
Stranges PM; Hutton DW; Collins CD
Value Health; 2013; 16(2):297-304. PubMed ID: 23538181
[TBL] [Abstract][Full Text] [Related]
17. Treating Clostridium difficile infection.
Shafran DM; Shafran SD
CMAJ; 2014 Apr; 186(7):531. PubMed ID: 24344151
[No Abstract] [Full Text] [Related]
18. Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections.
Weiss K; Allgren RL; Sellers S
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S110-5. PubMed ID: 22752858
[TBL] [Abstract][Full Text] [Related]
19. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.
Figueroa I; Johnson S; Sambol SP; Goldstein EJ; Citron DM; Gerding DN
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S104-9. PubMed ID: 22752857
[TBL] [Abstract][Full Text] [Related]
20. Fidaxomicin, a new treatment for Clostridium difficile infections.
Epstein L; Golan Y
Drugs Today (Barc); 2012 Feb; 48(2):101-8. PubMed ID: 22384450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
